A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Clinical trial NCT05736731 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05736731
Sponsor: A2 Biotherapeutics Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor, Adult Solid Tumor Pancreatic Cancer Pancreatic Neoplasms Pancreas Cancer Non Small Cell Lung Cancer Non Small Cell Lung Cancer Recurrent Non-Small Cell Squamous Lung Cancer NSCLC NSCLC, Recurrent Colorectal Cancer Colorectal Neoplasms

Start date: 2023-04-28
Primary completion: 2026-12-01
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.